Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 875

1.

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.

Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC.

Blood Cancer J. 2020 Feb 13;10(2):17. doi: 10.1038/s41408-020-0273-x. Review.

PMID:
32054831
2.

Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A study of the Greco-Israeli Collaborative Myeloma Working Group.

Katodritou E, Kastritis E, Gatt M, Cohen YC, Avivi I, Pouli A, Lalayianni A, Lavi N, Delimpasis S, Kyrtsonis MC, Michael M, Suriu C, Miri Z, Tzafarti K, Vadikoliou C, Maltezas D, Zikos P, Ganzel C, Vaxman Y, Aviv A, Christoforidou A, Gavriatopoulou M, Shaulov A, Verrou E, Papanota AM, Fakinos G, Gkioka AI, Palaska V, Triantafyllou T, Konstantinidou P, Anagnostopoulos A, Terpos E, Dimopoulos MA.

Am J Hematol. 2020 Feb 12. doi: 10.1002/ajh.25755. [Epub ahead of print]

PMID:
32048329
3.

Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

Bamias A, Tzannis K, Dimitriadis I, Tsironis G, Papatheorodidi AM, Tsiara A, Fragkoulis C, Xirokosta A, Barbarousi D, Papadopoulos G, Zakopoulou R, Varkarakis I, Mitsogiannis I, Adamakis I, Alamanis C, Stravodimos K, Papatsoris AG, Dellis AE, Drivalos A, Ntoumas K, Matsouka H, Halvatsiotis P, Raptis A, Gerotziafas GT, Dimopoulos MA.

Clin Genitourin Cancer. 2020 Jan 8. pii: S1558-7673(19)30394-5. doi: 10.1016/j.clgc.2019.12.021. [Epub ahead of print]

PMID:
32007440
4.

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.

Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J.

Leukemia. 2020 Jan 30. doi: 10.1038/s41375-020-0711-6. [Epub ahead of print]

PMID:
32001798
5.

Correction to: "Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May;30(5):860-862. doi: 10.1093/annonc/mdy466. Epub 2019 Dec 4. No abstract available.

PMID:
31987359
6.

Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.

Anargyrou K, Fotiou D, Vassilakopoulos TP, Christoulas D, Makras P, Dimou M, Ntanasis-Stathopoulos I, Masouridou S, Angelopoulou MK, Papatheodorou A, Tsionos K, Panayiotidis P, Dimopoulos MA, Terpos E.

Hemasphere. 2019 Sep 24;3(6):e303. doi: 10.1097/HS9.0000000000000303. eCollection 2019 Dec.

7.

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy.

Terpos E, Kostopoulos IV, Kastritis E, Ntanasis-Stathopoulos I, Migkou M, Rousakis P, Argyriou AT, Kanellias N, Fotiou D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ziogas DC, Papanota AM, Spyropoulou-Vlachou M, Trougakos IP, Tsitsilonis OE, Paiva B, Dimopoulos MA.

Hemasphere. 2019 Oct 1;3(6):e300. doi: 10.1097/HS9.0000000000000300. eCollection 2019 Dec.

8.

Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications.

Kokotis P, Manios E, Schmelz M, Fotiou D, Dialoupi I, Gavriatopoulou M, Roussou M, Lykka A, Dimopoulos MA, Kastritis E.

Amyloid. 2020 Jan 23:1-8. doi: 10.1080/13506129.2020.1713081. [Epub ahead of print]

PMID:
31971444
9.

JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.

Bagratuni T, Mavrianou N, Gavalas NG, Tzannis K, Arapinis C, Liontos M, Christodoulou MI, Thomakos N, Haidopoulos D, Rodolakis A, Kastritis E, Scorilas A, Dimopoulos MA, Bamias A.

Eur J Cancer. 2020 Feb;126:125-135. doi: 10.1016/j.ejca.2019.11.017. Epub 2020 Jan 9.

PMID:
31927213
10.

Prognostic role of microRNAs in breast cancer: A systematic review.

Zografos E, Zagouri F, Kalapanida D, Zakopoulou R, Kyriazoglou A, Apostolidou K, Gazouli M, Dimopoulos MA.

Oncotarget. 2019 Dec 24;10(67):7156-7178. doi: 10.18632/oncotarget.27327. eCollection 2019 Dec 24.

11.

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J.

Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.

PMID:
31836199
12.

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.

Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G, Martin T.

Future Oncol. 2020 Jan;16(2):4347-4358. doi: 10.2217/fon-2019-0431. Epub 2019 Dec 13.

13.

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.

Kastritis E, Roussou M, Gavriatopoulou M, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Ziogas DC, Fotiou D, Ntanasis-Stathopoulos I, Dialoupi I, Giannouli S, Tsirigotis P, Delimpasi S, Mparmparousi D, Spyropoulou-Vlachou M, Xirokosta A, Terpos E, Dimopoulos MA.

Blood Adv. 2019 Dec 10;3(23):4095-4103. doi: 10.1182/bloodadvances.2019000539.

14.

Multiple myeloma: Role of autologous transplantation.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA.

Cancer Treat Rev. 2020 Jan;82:101929. doi: 10.1016/j.ctrv.2019.101929. Epub 2019 Nov 11. Review.

PMID:
31770695
15.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group.

Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072.

PMID:
31735560
16.

Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease.

Kyriazoglou A, Ntanasis-Stathopoulos I, Terpos E, Fotiou D, Kastritis E, Dimopoulos MA, Gavriatopoulou M.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):57-62. doi: 10.1016/j.clml.2019.09.620. Epub 2019 Oct 9.

PMID:
31734019
17.

Insights on Multiple Myeloma Treatment Strategies.

Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P.

Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb. Review.

18.

Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.

Birmpilis AI, Karachaliou CE, Samara P, Ioannou K, Selemenakis P, Kostopoulos IV, Kavrochorianou N, Kalbacher H, Livaniou E, Haralambous S, Kotsinas A, Farzaneh F, Trougakos IP, Voelter W, Dimopoulos MA, Bamias A, Tsitsilonis O.

Cancers (Basel). 2019 Nov 9;11(11). pii: E1764. doi: 10.3390/cancers11111764.

19.

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.

Papanota AM, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA, Gavriatopoulou M.

J Blood Med. 2019 Aug 27;10:291-300. doi: 10.2147/JBM.S183997. eCollection 2019.

20.

Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process.

Papageorgiou L, Alhaj Hussen K, Thouroude S, Mbemba E, Cost H, Garderet L, Elalamy I, Larsen A, Van Dreden P, Dimopoulos MA, Mohty M, Gerotziafas GT.

TH Open. 2019 Nov 4;3(4):e340-e347. doi: 10.1055/s-0039-1700885. eCollection 2019 Oct.

21.

Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Moulopoulos LA, Manaios A, Fotiou D, Eleutherakis-Papaiakovou E, Migkou M, Bourgioti C, Terpos E, Kastritis E, Dimopoulos MA.

Medicine (Baltimore). 2019 Nov;98(44):e17794. doi: 10.1097/MD.0000000000017794.

22.

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.

Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J.

Leuk Lymphoma. 2019 Nov 5:1-11. doi: 10.1080/10428194.2019.1675881. [Epub ahead of print]

PMID:
31686561
23.

A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).

Dimopoulos MA, Cavo M, Mateos MV, Facon T, Heeg B, van Beekhuizen S, Gebregergish SB, Nair S, Pisini M, Lam A, Slavcev M.

Leuk Lymphoma. 2019 Nov 5:1-7. doi: 10.1080/10428194.2019.1682571. [Epub ahead of print]

PMID:
31686559
24.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA.

Expert Rev Anticancer Ther. 2019 Nov;19(11):921-928. doi: 10.1080/14737140.2019.1685879. Epub 2019 Nov 4.

PMID:
31679403
25.

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.

Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, Tsitsilonis O, Kostopoulos I, Terpos E, Dimopoulos MA.

Blood Adv. 2019 Oct 22;3(20):3002-3009. doi: 10.1182/bloodadvances.2019000147.

26.

Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.

Skorda A, Sklirou AD, Sakellaropoulos T, Gianniou DD, Kastritis E, Terpos E, Tsitsilonis OE, Florea BI, Overkleeft HS, Dimopoulos MA, Alexopoulos LG, Trougakos IP.

J Cell Mol Med. 2019 Dec;23(12):8010-8018. doi: 10.1111/jcmm.14653. Epub 2019 Sep 30.

27.

Screening for Gaucher disease among patients with plasma cell dyscrasias.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Fotiou D, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Kastritis E, Dimopoulos MA, Terpos E.

Leuk Lymphoma. 2019 Sep 30:1-3. doi: 10.1080/10428194.2019.1672059. [Epub ahead of print] No abstract available.

PMID:
31566473
28.

How I treat Waldenström macroglobulinemia.

Dimopoulos MA, Kastritis E.

Blood. 2019 Dec 5;134(23):2022-2035. doi: 10.1182/blood.2019000725.

PMID:
31527073
29.

Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis.

Zagouri F, Korakiti AM, Zakopoulou R, Kyriazoglou A, Zografos E, Haidopoulos D, Apostolidou K, Papatheodoridi MA, Dimopoulos MA.

Cancer Treat Rev. 2019 Sep;79:101885. doi: 10.1016/j.ctrv.2019.08.001. Epub 2019 Aug 6.

PMID:
31442939
30.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H.

Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.

31.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J.

Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19.

PMID:
31427722
32.

Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis.

Stamatelopoulos K, Georgiopoulos G, Athanasouli F, Nikolaou PE, Lykka M, Roussou M, Gavriatopoulou M, Laina A, Trakada G, Charakida M, Delialis D, Petropoulos I, Pamboukas C, Manios E, Karakitsou M, Papamichael C, Gatsiou A, Lambrinoudaki I, Terpos E, Stellos K, Andreadou I, Dimopoulos MA, Kastritis E.

Circ Res. 2019 Sep 27;125(8):744-758. doi: 10.1161/CIRCRESAHA.119.314862. Epub 2019 Aug 12.

33.

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH.

Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6.

PMID:
31388932
34.

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?

Kyriazoglou A, Zagouri F, Dimopoulos MA.

ESMO Open. 2019 Jun 25;4(3):e000479. doi: 10.1136/esmoopen-2018-000479. eCollection 2019.

35.

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Seval GC, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA.

Haematologica. 2020 Jan;105(1):201-208. doi: 10.3324/haematol.2019.219295. Epub 2019 Jul 5.

36.

Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?

Kleber M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E.

Expert Rev Hematol. 2019 Aug;12(8):651-663. doi: 10.1080/17474086.2019.1640115. Epub 2019 Jul 16.

PMID:
31268745
37.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25.

38.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O'Rourke L, Dimopoulos MA.

Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020.

39.

Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study.

Kalapanida D, Zagouri F, Gazouli M, Tsiakou A, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA.

Onco Targets Ther. 2019 May 28;12:4195-4202. doi: 10.2147/OTT.S189329. eCollection 2019.

40.

A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA.

Leukemia. 2019 Nov;33(11):2654-2661. doi: 10.1038/s41375-019-0431-y. Epub 2019 May 22.

PMID:
31118465
41.

Systemic therapy in cervical cancer: 30 years in review.

Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A.

Crit Rev Oncol Hematol. 2019 May;137:9-17. doi: 10.1016/j.critrevonc.2019.02.009. Epub 2019 Feb 28. Review.

PMID:
31014518
42.

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM.

J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.

PMID:
30990729
43.

Updates on thrombotic events associated with multiple myeloma.

Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, Migkou M, Dimopoulos MA, Terpos E.

Expert Rev Hematol. 2019 May;12(5):355-365. doi: 10.1080/17474086.2019.1604214. Epub 2019 Apr 14.

PMID:
30957573
44.

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.

Dimopoulos MA, Laubach JP, Echeveste Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, Kumar S, Labotka R, Lu V, Berg D, Byrne C, Teng Z, Liu G, van de Velde H, Richardson PG.

Eur J Haematol. 2019 Jun;102(6):494-503. doi: 10.1111/ejh.13231. Epub 2019 May 8.

PMID:
30943323
45.

Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies.

Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Gavriatopoulou M, Sergentanis IN, Dimopoulos MA, Psaltopoulou T.

Leuk Lymphoma. 2019 Aug;60(8):1978-1990. doi: 10.1080/10428194.2018.1563693. Epub 2019 Mar 26.

PMID:
30912696
46.

Discrepancies of current recommendations in breast cancer follow-up: a systematic review.

Kyriazoglou A, Zagouri F, Fotiou D, Dimitrakakis C, Marinopoulos S, Zakopoulou R, Kaparelou M, Zygogianni A, Dimopoulos MA.

Breast Cancer. 2019 Sep;26(5):681-686. doi: 10.1007/s12282-019-00963-6. Epub 2019 Mar 18.

PMID:
30887287
47.

Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.

Trakada G, Kastritis E, Gavriatopoulou M, Velentza L, Fotiou D, Ziogas DC, Panagiotidis I, Eleutherakis-Papaiakovou E, Roussou M, Migkou M, Kanellias N, Ntanasis-Stathopoulos I, Kallianos A, Terpos E, Dimopoulos MA.

Ann Hematol. 2019 Jun;98(6):1427-1434. doi: 10.1007/s00277-019-03641-x. Epub 2019 Mar 5.

PMID:
30834954
48.

A 50-Year-Long Study of Waldenström Macroglobulinemia.

Kastritis E, Dimopoulos MA.

Mayo Clin Proc. 2019 Mar;94(3):394-396. doi: 10.1016/j.mayocp.2019.01.021. No abstract available.

PMID:
30832789
49.

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop.

Bagratuni T, Sklirou AD, Kastritis E, Liacos CI, Spilioti C, Eleutherakis-Papaiakovou E, Kanellias N, Gavriatopoulou M, Terpos E, Trougakos IP, Dimopoulos MA.

Sci Rep. 2019 Mar 1;9(1):3245. doi: 10.1038/s41598-019-39672-7.

50.

Anti-BCMA antibodies in the future management of multiple myeloma.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E.

Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326. doi: 10.1080/14737140.2019.1586539. Epub 2019 Mar 18.

PMID:
30810049

Supplemental Content

Loading ...
Support Center